Clinical-pathological characteristics of patients with (n = 34) and without (n = 102) a CHEK2*1100delC mutation at the time of diagnosis of the first primary breast cancer
| CHEK2mutation present(n = 34) | CHEK2mutation absent(n = 102) | Diff. | |
|---|---|---|---|
| Diff., difference. | |||
| †According to Bloom-Richardson’s grading. | |||
| Age (mean; SD; range) | 49.0; 11.6; 25–83 | 48.4; 11.9; 23–86 | t = 0.26;p = 0.80 |
| Tumour size | |||
| 2 cm or less | 16 (53%) | 49 (53%) | |
| More than 2 cm | 14 (47%) | 43 (47%) | χ2 = 0.00 |
| Unknown | 4 | 10 | p = 0.99 |
| Axillary nodal status | |||
| Negative | 14 (40%) | 43 (44%) | |
| Positive | 19 (60%) | 53 (56%) | χ2 = 0.06 |
| Unknown | 1 | 6 | p = 0.81 |
| Tumour stage | |||
| DCIS | 2 (7%) | 5 (6%) | |
| I–II | 22 (73%) | 74 (87%) | |
| III–IV | 6 (20%) | 6 (7%) | χ2 = 4.08 |
| Unknown | 4 | 17 | p = 0.13 |
| Histological tumour type | |||
| Ductal invasive | 25 (73%) | 79 (84%) | |
| Lobular invasive | 4 (12%) | 8 (9%) | |
| DCIS | 2 (6%) | 5 (5%) | |
| Other | 3 (9%) | 3 (2%) | χ2 = 3.50 |
| Unknown | – | 7 | p = 0.32 |
| Oestrogen receptor status | |||
| Negative | 2 (9%) | 22 (31%) | |
| Positive | 21 (91%) | 48 (69%) | χ2 = 4.67 |
| Unknown | 11 | 32 | p = 0.03 |
| Progesterone receptor status | |||
| Negative | 3 (19%) | 25 (47%) | |
| Positive | 13 (81%) | 27 (53%) | χ2 = 4.35 |
| Unknown | 19 | 50 | p = 0.04 |
| Grade† | |||
| Good (grade I) | 4 (19%) | 12 (15%) | |
| Moderate (grade II) | 11 (52%) | 34 (44%) | |
| Bad (grade III) | 6 (29%) | 32 (41%) | χ2 = 1.09 |
| Unknown | 13 | 24 | p = 0.58 |
| Surgical procedure | |||
| Breast conserving | |||
| therapy | 17 (52%) | 40 (40%) | |
| Breast conserving therapy with sentinel | 1 (3%) | 5 (5%) | |
| node procedure | |||
| Mastectomy | 14 (42%) | 50 (49%) | |
| Mastectomy with | 1 (3%) | 4 (4%) | |
| sentinel node | |||
| procedure | |||
| Other | – | 2 (2%) | χ2 = 2.01 |
| Unknown | 1 | 1 | p = 0.74 |
| Resection line involved | |||
| No | 27 (87%) | 81 (88%) | |
| Yes | 4 (13%) | 11 (12%) | χ2 = 0.02 |
| Unknown | 3 | 10 | p = 0.89 |
| Adjuvant systemic therapy | |||
| No | 13 (40%) | 39 (39%) | |
| Chemotherapy | 9 (27%) | 18 (18%) | |
| Endocrine therapy | 3 (9%) | 13 (13%) | |
| Combination of both | 8 (24%) | 30 (30%) | χ2 = 1.66 |
| Unknown | 1 | 2 | p = 0.65 |
| Adjuvant radiotherapy | |||
| No | 9 (27%) | 29 (29%) | |
| Yes | 24 (73%) | 71 (71%) | χ2 = 0.04 |
| Unknown | 1 | 2 | p = 0.85 |